Core Viewpoint - Zhijiang Biotech experienced a decline of 5.03% on September 23, with a stock price of 22.86 CNY per share and a total market capitalization of 4.393 billion CNY [1] Company Overview - Zhijiang Biotech, established on April 18, 2005, and listed on January 18, 2021, is located in Minhang District, Shanghai. The company specializes in the research, production, and sales of molecular diagnostic reagents and equipment [1] - The revenue composition of the company includes 86.47% from nucleic acid testing kits, 11.99% from other products, and 1.54% from molecular diagnostic instruments [1] Shareholder Information - Among the top ten circulating shareholders of Zhijiang Biotech, a fund under Rongtong Fund holds 1.5 million shares, unchanged from the previous period, representing 0.78% of the circulating shares. The estimated floating loss today is approximately 1.815 million CNY [2] - The Rongtong Health Industry Flexible Allocation Mixed A/B fund (000727) was established on December 25, 2014, with a current scale of 2.074 billion CNY. Year-to-date returns are 19.74%, ranking 4408 out of 8172 in its category, while the one-year return is 46.63%, ranking 3544 out of 7995 [2] Fund Manager Information - The fund manager of Rongtong Health Industry Flexible Allocation Mixed A/B is Wan Minyuan, who has been in the position for 9 years and 31 days. The total asset scale of the fund is 5.629 billion CNY, with the best return during his tenure being 155.09% and the worst being -17.06% [3]

本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海之江生物科技股份有限公司（以下简称"公司"）产品猴痘病毒核酸检 测试剂盒（荧光 PCR 法）于近日收到世界卫生组织（以下简称"WHO"）通知， 于 2025 年 9 月 17 日被列入为 WHO 应急使用清单（英文全称"Emergency Use Listing"，以下简称"EUL"）。现将具体情况公告如下： | 产品名称 | Monkeypox Virus Lyo-PCR Kit | | --- | --- | | | 猴痘病毒核酸检测试剂盒（荧光 PCR 法） | | 申请号 | MPXV-13393-139-00 | | 产品编码 | W-ZD-0580-02-48A,W-ZD-0580-02-96A | | 批准时间 | 2025 年 9 月 17 日 | | 使用期限 | 如无特殊情况，该产品的采购期限为 1 年 | | | 公司将持续按照 WHO 法规和指南满足 WHO EUL 项目的要求。若不 | | 其他 | 能满足相关条件，则产品可能面临 WHO 的矫正措 ...

Core Viewpoint - The company, Zhijiang Biotech (688317.SH), has received notification from the World Health Organization (WHO) that its monkeypox virus nucleic acid test kit (using fluorescent PCR method) will be included in the WHO Emergency Use Listing (EUL) by September 17, 2025, indicating WHO's recognition and endorsement of the product [1] Group 1 - The inclusion of the monkeypox product in the WHO EUL provides a basis for procurement for WHO member countries and potential buyers [1] - This recognition is expected to facilitate the promotion and sales of the company's monkeypox products in relevant overseas markets [1]

人民财讯9月18日电，之江生物(688317)9月18日公告，公司产品猴痘病毒核酸检测试剂盒(荧光PCR法) 于近日收到世界卫生组织(简称"WHO")通知，于2025年9月17日被列入为WHO应急使用清单。 ...

Core Viewpoint - The company Zhijiang Biotech (688317.SH) has received notification from the World Health Organization (WHO) that its monkeypox virus nucleic acid test kit (fluorescent PCR method) has been included in the WHO Emergency Use Listing (EUL) effective September 17, 2025, indicating recognition and endorsement from WHO [1] Group 1 - The inclusion of the product in the WHO EUL provides a basis for procurement for WHO member countries and potential buyers [1] - This recognition is expected to facilitate the promotion and sales of the company's monkeypox products in relevant overseas markets [1]

上述产品被列入WHO EUL，表明WHO对公司产品的认可和肯定，可为WHO成员国和各意向采购方提 供采购依据，对公司猴痘产品在相关海外市场的推广和销售起到推动作用。 智通财经APP讯，之江生物(688317.SH)发布公告，公司产品猴痘病毒核酸检测试剂盒(荧光PCR法)于近 日收到世界卫生组织(以下简称"WHO")通知，于2025年9月17日被列入为WHO应急使用清单(英文全 称"Emergency Use Listing"，以下简称"EUL")。 ...

Core Viewpoint - The company, Zhijiang Biologics (688317.SH), has received notification from the World Health Organization (WHO) that its monkeypox virus nucleic acid testing kit (fluorescent PCR method) has been included in the WHO Emergency Use Listing (EUL) as of September 17, 2025, indicating WHO's recognition and endorsement of the product [1] Group 1 - The inclusion in the WHO EUL provides a procurement basis for WHO member countries and potential buyers, which is expected to facilitate the promotion and sales of the company's monkeypox products in relevant overseas markets [1]

Core Viewpoint - The company’s monkeypox virus nucleic acid testing kit has been included in the WHO Emergency Use Listing (EUL) as of September 17, 2025, indicating recognition and endorsement from WHO [1] Group 1: Product Recognition - The inclusion in the EUL provides a procurement basis for WHO member states and potential buyers, enhancing the promotion and sales of the company's monkeypox product in overseas markets [1] Group 2: Market Risks - The product faces market competition risks, the possibility of being removed from the EUL, and uncertainties regarding its impact on profitability [1]

Core Viewpoint - Zhijiang Biology (688317.SH) is currently experiencing a decline in stock price, closing at 25.11 yuan with a drop of 2.90%, resulting in a total market capitalization of 4.825 billion yuan, indicating the stock is in a state of breaking below its initial public offering price [1] Group 1: Company Overview - Zhijiang Biology was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on January 18, 2021, with an issuance of 48,676,088 shares at an initial price of 43.22 yuan per share [1] - The highest stock price recorded was 93.80 yuan, reached on the sixth trading day after the IPO [1] Group 2: Fundraising and Financials - The total amount raised from the initial public offering was 2.10378 billion yuan, with a net amount of 1.94232 billion yuan, exceeding the original plan by 586.43 million yuan [1] - The company initially planned to raise 1.35589 billion yuan, which was intended for various projects including the upgrade of in vitro diagnostic reagent production lines and the establishment of a molecular diagnostic engineering research center [1] - The total issuance costs amounted to 161.4589 million yuan, with underwriting and sponsorship fees accounting for 144.9505 million yuan [1]

法律意见书 浙江天册律师事务所 关于 上海之江生物科技股份有限公司 2025 年第一次临时股东大会的 法律意见书 浙江省杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼 310007 电话：0571-87901111 传真：0571-87901500 法律意见书 编号：TCYJS2025H1473 号 致：上海之江生物科技股份有限公司 浙江天册律师事务所（以下简称"本所"）接受上海之江生物科技股份有限 公司（以下简称"之江生物"或"公司"）的委托，指派本所律师参加公司 2025 年第一次临时股东大会，并根据《中华人民共和国证券法》（以下简称"《证券 法》"）、《中华人民共和国公司法》（以下简称"《公司法》"）和《上市公 司股东会规则》（以下简称"《股东会规则》"）等法律、法规和其他有关规范 性文件的要求出具本法律意见书。 法律意见书 浙江天册律师事务所 关于上海之江生物科技股份有限公司 2025 年第一次临时股东大会的 在本法律意见书中，本所律师仅对本次股东大会召集、召开程序、出席人员 的资格、召集人的资格、表决程序及表决结果的合法有效性发表意见，不对会议 所审议的议案内容和该等议案中所表述的事实或数据的真 ...